Stay up to date every week with the european biotechnology newsletter.

Phone

This field is for validation purposes and should be left unchanged.

Email(Required)

This field is hidden when viewing the form

EBcom NL

confirm list

This field is hidden when viewing the form

Consent

I agree to the privacy policy.

Stay up to date every week with the european biotechnology newsletter.

Phone

This field is for validation purposes and should be left unchanged.

Email(Required)

This field is hidden when viewing the form

EBcom NL

confirm list

This field is hidden when viewing the form

Consent

I agree to the privacy policy.

go to the article

go back to the homepage

BIOCOM CARD
Newsletter
Advertising
Job Market
Shop

Latest news
Background
Opinion
The Mag
Euro Biotech Guide
Market Place
Associations
Service
Events
Search
Menu Menu

LATEST NEWS

Recipharm in €68m Mitim takeover

Recipharm remains on track for growth. The Swedish CDMO is acquiring Italian injectable beta lactam expert Mitim Srl. The takeover is worth €68.4m. more ➔

Page 213 of 213«‹211 212213

BACKGROUND

ADC success starts with the antibody — the key to balancing efficacy and safety.

Yumab GmbH

Antibodies: Cornerstone of ADC precision and effica...

Concept Heidelberg GmbH

From method validation to the life-cycle

Tenthpin

CDMO: An SAP S/4HANA transformation in <10 months

MAGAZINE

1 / 4

Investors are showing enormous interest in the topic of longevity, as well as in combating chronic diseases. This is because these diseases have a negative impact on life expectancy. The USA and China … more ➔

2 / 4

This issue focuses on the art of upscaling industrial biotechnology in Europe, the impact of the Trump factor on the life sciences and the European Commission's new billion-euro fund for emerging … more ➔

3 / 4

This issue offers insights into Europe's fight for green solutions for a bioeconomy, antimicrobial resistance and how Europe is preparing for the next pandemic. more ➔

4 / 4

Since the first antibody drug was approved back in 1986, monoclonal antibodies have emerged as the dominant class in the global US$417bn market for biologics. At the end of 2023, sales stood at more … more ➔

Link to LinkedIn
Link to Instagram

Contact
Imprint
Privacy policy

Scroll to top